List view / Grid view
9 September 2013 | By Merck
Merck announced that the NDA for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. FDA...
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
9 September 2013 | By Merck
Merck and Maccabi Healthcare Services are starting a new, multi-year agreement...
8 September 2013 | By Novartis
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler®...
6 September 2013 | By Takeda
FDA has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis...
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
5 September 2013 | By Capsugel
Capsugel and Bend Research have entered into a definitive agreement for Capsugel to acquire Bend Research as part of its DFS business unit...
5 September 2013 | By GlaxoSmithKline
In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed...
4 September 2013 | By Merck
Merck has received approval from the U.S. FDA to manufacture bulk varicella at the company’s site in Durham...
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
4 September 2013 | By Abbott
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013...
